US Stock MarketDetailed Quotes
CKPT Checkpoint Therapeutics
- 1.900
- +0.010+0.53%
Close May 31 16:00 ET
- 1.910
- +0.010+0.53%
Post 19:50 ET
70.02MMarket Cap-727P/E (TTM)
1.925High1.840Low156.51KVolume1.890Open1.890Pre Close295.05KTurnover0.59%Turnover RatioLossP/E (Static)36.85MShares3.62052wk High-6.83P/B50.30MFloat Cap1.30052wk Low--Dividend TTM26.48MShs Float105.000Historical High--Div YieldTTM4.50%Amplitude1.300Historical Low1.885Avg Price1Lot Size
About Checkpoint Therapeutics Company
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Company Profile
SymbolCKPT
Company NameCheckpoint Therapeutics
Listing DateJun 26, 2017
Founded2014
CEOMr. James F. Oliviero, III
MarketNASDAQ
Employees23
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address95 Sawyer Road,Suite 110
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-781-652-4500
Websitehttp://www.checkpointtx.com
Company Executives
- Name
- Position
- Salary
- James F. Oliviero, III
- Director, President and Chief Executive Officer
- 1.64M
- Garrett Gray
- Chief Financial Officer, Corporate Secretary and Treasurer
- 712.88K
- Michael S. Weiss
- Chairman of the Board
- 110.00K
- Dr. Lindsay A. Rosenwald, M.D.
- Director
- 100.00K
- Dr. Amit Sharma, F.A.C.P.
- Independent Director
- --
- Barry Salzman
- Independent Director
- 100.00K
- Neil Herskowitz
- Independent Director
- 110.00K
- Christian Bechon
- Independent Director
- 100.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg